Haldemann A R
Universitätsklinik, Kantonsspital Basel.
Ther Umsch. 1999 Jul;56(7):403-7. doi: 10.1024/0040-5930.56.7.403.
Radioiodine therapy of differentiated thyroid cancer is based on the ability of these tumors to accumulate iodine, making them accessible to a metabolic treatment with I-131, a beta-emitting radioisotope leading to in intensive, highly selective and tumoricidal irradiation of such cells. Radioiodine ablation of thyroid remnants is performed few weeks after radical thyroid surgery and significantly decreases the risk of recurrence of thyroid cancer and the risk of death due to thyroid cancer. Even in recurrent or metastatic thyroid cancer, radioiodine treatment will often be curative or at least result in long term improvement, making differentiated thyroid cancers among the most curable cancers at present. In Switzerland, radioiodine treatment of thyroid cancer must be done in specialized nuclear medicine wards. Secondary effects are mild and mostly related to the symptoms of hypothyroidism. Recurrent or metastatic thyroid cancer often necessitates an interdisciplinary approach, including surgery, radioiodine therapy and sometimes external radiation therapy. Follow-up should be done in specialized centers in collaboration with the patient's family doctor.
分化型甲状腺癌的放射性碘治疗基于这些肿瘤摄取碘的能力，这使得它们能够接受用I-131进行的代谢治疗，I-131是一种发射β射线的放射性同位素，可对这类细胞进行强烈、高度选择性的杀肿瘤照射。甲状腺全切术后数周进行甲状腺残余组织的放射性碘清除，可显著降低甲状腺癌复发风险以及因甲状腺癌导致的死亡风险。即使是复发性或转移性甲状腺癌，放射性碘治疗通常也能治愈，或至少带来长期改善，这使得分化型甲状腺癌成为目前最可治愈的癌症之一。在瑞士，甲状腺癌的放射性碘治疗必须在专门的核医学病房进行。副作用轻微，主要与甲状腺功能减退的症状有关。复发性或转移性甲状腺癌通常需要多学科方法，包括手术、放射性碘治疗，有时还需要外部放射治疗。应在专门中心与患者的家庭医生合作进行随访。
